EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis

Yao Shu, Heng Zhang, Alessandro Lugli, Femke Simmer, Iris D. Nagtegaal

Histopathology · 2026-12 · 89 (6) · 927-940

DOI: 10.1111/his.70225 ↗
AbstractBibliografische Angaben

Abstract

Aims Tumour budding (TB) has been recognized as an additional prognostic factor in the TNM (2017) and WHO (2019) classification systems. However, its prognostic impact in stages II and III colorectal cancer (CRC) remains inconsistently defined. This study aims to systematically evaluate the prognostic value of high‐grade TB in stage II–III CRC. Methods and results A systematic search of PubMed, Embase and Cochrane Library was conducted to identify studies reporting the association between high‐grade TB and survival outcomes in stage II–III CRC. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for disease‐free survival (DFS), overall survival (OS) and cancer‐specific survival (CSS) were calculated using random‐effects models. A total of 43 studies involving 17,831 patients were included. Univariable analysis showed that high‐grade TB was significantly associated with worse DFS (HR 2.53, 95% CI 2.14–3.00), OS (HR 2.40, 95% CI 1.69–3.42) and CSS (HR 3.37, 95% CI 2.19–5.19). Multivariable analysis confirmed the independent prognostic value of high‐grade TB for all three outcomes. Subgroup analysis stratified by TNM stage revealed that high‐grade TB consistently predicted adverse outcomes in both stage II and stage III disease. Conclusions This study confirms that high‐grade TB is an independent prognostic factor in stage II–III CRC, consistently associated with worse DFS, OS and CSS. Incorporating TB into routine histopathological assessment may improve risk stratification and help identify high‐risk patients, although its role in guiding therapeutic decisions requires further prospective validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →